A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL in 2022

Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)

Steven M. Horwitz, MD
Program Director Pamela B. Allen, MD Pierluigi Porcu, MD Released: August 8, 2022

Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)

Jesús G. Berdeja, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 5, 2022 Expired: August 4, 2023

Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)

Elizabeth Brém, MD
Program Director Christopher R. Flowers, MD, MS
Program Director Pallawi Torka, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 3, 2022 Expired: August 2, 2023

Pharmacists review the latest findings in the treatment of relapsed/refractory multiple myeloma and provide clinical insights based on their personal experiences, from Clinical Care Options (CCO).

Rebecca Gonzalez, PharmD, BCOP Donald C. Moore, PharmD, BCPS, BCOP, DPLA Released: July 29, 2022